ID

28181

Descrizione

NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln

Keywords

versioni (5)

1. 26/12/17 26/12/17 -
2. 27/12/17 27/12/17 -
3. 15/03/21 15/03/21 - Dr. rer. medic Philipp Neuhaus
4. 13/04/21 13/04/21 - Dr. rer. medic Philipp Neuhaus
5. 20/09/21 20/09/21 -

Titolare del copyright

Universität zu Köln

Caricato su

27 dicembre 2017

DOI

10.21961/mdm:28181

Licenza